Profil
Raymond Kaempfer was the founder of Atox Bio Ltd., which was founded in 2003, where he held the title of Chief Scientific Officer from 2003 to 2011.
He is currently a Member of the European Molecular Biology Organization.
Dr. Kaempfer's former positions include being a Faculty Member at Harvard University and a Professor of Molecular Biology & Cancer Research at The Hebrew University of Jerusalem.
Dr. Kaempfer received a doctorate degree from the Massachusetts Institute of Technology.
Postes actifs de Raymond Kaempfer
| Sociétés | Poste | Début |
|---|---|---|
European Molecular Biology Organization | Corporate Officer/Principal | - |
Anciens postes connus de Raymond Kaempfer
| Sociétés | Poste | Fin |
|---|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Fondateur | - |
Formation de Raymond Kaempfer
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
European Molecular Biology Organization | |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Health Technology |
















